ClinicalTrials.gg
CompletedNCT07138352XS003-14Updated Aug 22, 2025

Bioavailability Study of XS003 (Nilotinib)

A Phase 1 interventional study of XS003 under fed and fasted condition in Cancer, sponsored by Xspray Pharma AB. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Xspray Pharma AB · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.
  • Registered 9 months after the study started (first participant enrolled Oct 2024, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

An open label, single-center, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study under fasted and fed conditions.

Read the detailed description

This is a single-dose, open-label, randomized, crossover study to evaluate the comparative oral bioavailability of XS003 (nilotinib) Capsules 192 mg (4X 48 mg) of Xspray Pharma AB, Sweden under fasted conditions comparing with XS003 (nilotinib) Capsules 192 mg (4X 48 mg) of Xspray Pharma AB, Sweden in healthy, adult, human subjects under fed conditions.

This will enroll up to 48 healthy, adult, human subjects. Each sequence will enroll 24 healthy, adult, human subjects. There will be at least 10 days between each drug administration.

Adverse events will be recorded from the signing of ICF throughout the study. In each period, the subjects will be housed for approximately 14 hours before and at least 24 hours after the drug administration. Subjects will return to clinical facility for ambulatory samples at 48.00, 72.00, 96.00 and 120.00 hours post dose.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 48 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Xspray Pharma AB is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A willing study participant to become eligible for the study must fulfil all of the below inclusion criteria.
  • Healthy, human beings 18 and 55 years of age inclusive at the time of screening.
  • Subjects, having a between ≥18.0 kg/m2 and \<32.0 kg/m2.
  • Subjects must be able to provide written .
  • Acceptable medical history, physical examination, , laboratory investigations per the Investigator.
  • Female subjects must meet at least one of the following requirements:

    • Agree to abstain from sexual intercourse from screening, throughout the duration of the study and for at least 90 days after the last study drug administration.
    • Have used and agree to continue to use a reliable method of (e.g., hormonal contraceptives, condom with spermicide, IUD) for at least 30 days before initial dosing, throughout the duration of the study and for at least 90 days after the last study drug administration.
    • Surgically sterile (bilateral oophorectomy or hysterectomy, bilateral tubal ligation at least 3 months before initial dosing or Essure® device placement).
    • At least 1 year and have a documented FSH level ≥ 40 mIU/mL at screening.
  • Male subjects who are not surgically sterile must agree to abstain from sexual intercourse (complete abstinence) or use appropriate contraceptive measures and agree to not impregnate a female partner(s) and not to donate sperm throughout the entire study, including the , and for at least 90 days after the last study drug administration. Examples of acceptable methods of contraception include a double-barrier method of contraception (e.g., condom with spermicide). Other forms of contraception may be acceptable, at the discretion of the Investigator.
  • Clinical laboratory values should be within the laboratory's stated normal range. If not within this range, they must be without clinical significance, as determined by the Investigator (with the exception of those labs specifically listed in Section 9.2.).
  • The subject is able to communicate meaningfully with study personnel and is anticipated to be able to comply fully with study procedures and must be willing and able to communicate and participate in the whole study.
  • Male subjects should not donate sperm during the study and for 90 days after the last administration of IMP.

Exclusion criteria

Exclusion Criteria:

  • A willing study participant will be excluded from the study, if any of the below criteria is met.
  • Systolic blood pressure is less than 100 mm of Hg or more than 140 mm of Hg.
  • Diastolic blood pressure is less than 60 mm of Hg or more than 90 mm of Hg.
  • Note: If vital signs are out-of-range, the investigator may obtain one additional reading so that up to 2 consecutive assessments are made within 1.00 hour with the subject seated quietly during the 5 minutes preceding the assessment.
  • Body temperature less than 95.0 °F (35.0 °C) or more than 98.6°F (37.0°C).
  • Heart rate less than 60/min or more than 100/min.
  • History of or idiosyncratic reaction to drug product or any other related drugs.
  • History of , cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, or psychiatric disease or disorder considered in the opinion of the Investigator.
  • Taken drugs that are substrates or inhibitors of P-glycoproteins in last 30 days prior to the check-in.
  • History of hematological, malignant, and bleeding disorders.
  • On anticoagulant therapy, within 4 weeks prior to the check-in.
  • History of hypokalemia, hypomagnesemia, or a history of cardiac disease.
  • History of cholecystectomy or gall stones.
  • History of any drug or alcohol abuse in the past 2 years.
  • History of intake of strong inhibitors (see Table 5) or inducers within 4 weeks prior to the check-in.
  • History of intake of drugs known to prolong the within 4 weeks prior to the check-in
  • History of rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose-containing products, or of glucose- galactose malabsorption.
  • A prolonged QTc interval (QTcF greater than 450 msec demonstrated on at Screening.)
  • Any clinically significant ECG abnormalities that, in the Investigator's opinion, would compromise the subject's safety.
  • History or family history of long QT syndrome.
  • Significant history or current evidence of risk factors for Torsade de Pointes (TdP).
  • History of Gilbert syndrome.
  • Having poor vein access.
  • Male subjects with pregnant or breastfeeding partners.
  • Taking, or have taken, any prescribed or over-the-counter drug or herbal remedies, vitamins, or minerals and intake of any medication except caffeine, ranitidine, paracetamol, diclofenac sodium and ondansetron within 14 days before check-in (other than up to 4 g of paracetamol/acetaminophen per day).
  • Consumption of xanthine containing food or beverages (like tea, coffee, chocolates, and flavored drinks) within 48 hours before check-in of each period.
  • Consumption of grapefruit or grapefruit juice, pomegranate, or pomegranate juice, pomelo, starfruit, Seville oranges and St. John's Wort within 14 days before check-in.
  • Consumption of tobacco containing products (including smoking cigarettes or chewing tobacco products), e-cigarettes and/or nicotine replacement products within 3 months before check-in.
  • Consumption of alcoholic beverages within 48 hours before check-in.
  • Positive drugs of abuse screen at Screening or upon check-in of any period. Based on local regulations, if positive for tetrahydrocannabinol, evaluation will be performed by the PI based on last usage date (must be at least 14 days prior to the initial dosing and throughout the duration of the entire study period).
  • Positive alcohol (breath or urine) test screen at screening or upon check-in of any period.
  • Positive urine cotinine test screen at screening or upon check-in of any period.
  • Participated in any other clinical study or donated blood within 30 days before check-in.
  • Positive screens for serum virus surface antigen (HBsAg), virus antibody ( HCV Ab) or (HIV-1 \& 2).
  • Participated in contact sports or unaccustomed strenuous exercise within 72 hours before check-in of any period.
  • History of clinically significant allergy or any allergy or sensitivity to nilotinib, or history of any food or drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  • Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction especially cardiovascular disorders (e.g., arterial vascular occlusive events), respiratory disorders, renal or hepatic disorders, diabetes, or obesity.
  • Subjects with greater than the safety laboratory values of ALP, , AST and total .
  • Estimated (eGFR) \< 90 mL/min at screening
  • Subjects with less than the safety laboratory lower limit of normal values for potassium or magnesium.
  • Clinically significant history or presence of gastrointestinal disease or history of malabsorption within the last year, as determined by the Investigator.
  • Positive pregnancy test (for females) at screening or upon check-in of any period.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    XS003 fasted condition

    XS003 (nilotinib) Capsules 192 mg (4X 48 mg) under fasted conditions.

    Drug: XS003 under fed and fasted condition

  • Experimental
    XS003 fed condition

    XS003 (nilotinib) Capsules 192 mg (4X 48 mg) under fed conditions

    Drug: XS003 under fed and fasted condition

Interventions

  • DrugXS003 under fed and fasted condition

    XS003 under fed and fasted condition

06

What researchers measure

Primary outcomes

  1. To evaluate the comparative bioavailability Cmax of XS003 (nilotinib) Capsules 192 mg (4X 48 mg) under fasted and fed conditions in healthy, adult, human subjects.

    Primary PK endpoints: Cmax: Maximum measured analyte concentration in the biological fluid.

    Time frame: PK samples will be collected at pre-dose (0.00) and between 0.50 and 120.00 hours post dose

  2. To evaluate the comparative bioavailability AUC of XS003 (nilotinib) Capsules 192 mg (4X 48 mg) under fasted and fed conditions in healthy, adult, human subjects.

    Primary PK endpoints: AUC0-t: Time of the maximum observed drug concentration.

    Time frame: PK samples will be collected at pre-dose (0.00) and between 0.50 and 120.00 hours post dose

Secondary outcomes

  1. To evaluate the safety (adverse events (AE)) of XS003 (nilotinib) Capsules 192 mg (4X 48 mg) under fasted and fed conditions in healthy, adult, human subjects.

    To collect data on treatment related and non treatment related adverse events as assessed by CTCAE v4.0"

    Time frame: From Screening until end of study, i.e. up to 56days

  2. To evaluate the safety and tolerability (ECG, elektrocardiogram) of XS003 (nilotinib) Capsules 192 mg (4X 48 mg) under fasted and fed conditions in healthy, adult, human subjects.

    Safety variables collection will include ECG, elektrocardiogram QT Interval

    Time frame: From Screening until end of study, i.e. up to 56days

07

Study locations

1 site
  • QPS Missouri
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: No — This is an Bioavailibility study so IPD is N/A

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jan 2025, 3 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 3 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 22, 2025
StartActual
Oct 3, 2024
Primary completionActual
Jan 8, 2025
CompletionActual
Jan 8, 2025
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07138352
Lead sponsor
Xspray Pharma AB
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Oct 3, 2024
Primary completion
Jan 8, 2025
Completion
Jan 8, 2025
Last update
Aug 22, 2025

Study contacts

Maria Klockare
study director · Xspray Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion